Experience of biospecific hemosorbtion by using «Hemoproteazosorb» sorbent in patients with acute pancreatitis

Abstract

Objective. To provide a clinical assessment of the effectiveness of biospecific hemosorption using the sorbent “Hemoproteazosorb” in patients with severe acute pancreatitis; to substantiate the importance of this method in a comprehensive approach to the treatment of the disease.

Materials and methods. The analyses of clinical cases of 61 patients with acute pancreatitis over 2023, whose therapy was supplemented with biospecific hemosorption and other methods of extracorporeal detoxification, was conducted. Clinical aspects of the disease, the results of laboratory and instrumental research methods, as well as the survival, mortality indices and subsequent development of complications were compared.

Results. The analyses of obtained data demonstrated efficacy of the sorbtion method in initial stages of the disease treatment, patients’ survival growth and time shortening of stay in the anesthesiology, resuscitation and intensive care department, and a decrease in the percentage of development of purulent-septic complications in future.

Conclusion. Biospecific hemosorbtion with the sorbent «Hemoproteazosorb» in acute pancreatitis as a part of a comprehensive treatment approach has proven to be an effective therapy method that significantly improves patients’ chances of a favorable outcome.